Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + tacrolimus + methylprednisolone for moderate-high risk idiopathic membranous nephropathy
TCTR20260515001Phase 4Completed
- Sponsor
- Binzhou People's Hospital
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rituximab, tacrolimus and methylprednisolone in idiopathic membranous glomerulonephritis (IMG), sponsored by Binzhou People's Hospital. Started Oct 2021; status: completed.
02
Drugs
rituximabtacrolimusmethylprednisolone
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on TCTR20260515001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260515001.